SOTAC Stock Overview
Engages in the production, manufacturing, processing, and sale of various pharmaceutical products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Sotac Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹104.75 |
| 52 Week High | ₹202.80 |
| 52 Week Low | ₹87.10 |
| Beta | 0 |
| 1 Month Change | -4.12% |
| 3 Month Change | -16.47% |
| 1 Year Change | -14.14% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -13.25% |
Recent News & Updates
Recent updates
Here's Why We Think Sotac Pharmaceuticals (NSE:SOTAC) Is Well Worth Watching
Sep 28
We Think Sotac Pharmaceuticals (NSE:SOTAC) Is Taking Some Risk With Its Debt
Jul 24Sotac Pharmaceuticals Limited's (NSE:SOTAC) 31% Price Boost Is Out Of Tune With Earnings
Jun 28Sotac Pharmaceuticals Limited (NSE:SOTAC) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Feb 29Shareholder Returns
| SOTAC | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.0% | -7.5% | -5.6% |
| 1Y | -14.1% | 9.0% | -0.9% |
Return vs Industry: SOTAC underperformed the Indian Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: SOTAC underperformed the Indian Market which returned -0.9% over the past year.
Price Volatility
| SOTAC volatility | |
|---|---|
| SOTAC Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine SOTAC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 68 | Sharadkumar Patel | sotacpharma.com |
Sotac Pharmaceuticals Limited engages in the production, manufacturing, processing, and sale of various pharmaceutical products in India. Its therapeutic product portfolio includes anti-diabetic, anti-psychotic, vitamins, minerals, iron, anti-cold, anti-allergic, dermatological products, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics IP-lactams and non-IP-lactams, anti-fungal, and cephalosporin. The company also offers beta and non-beta-lactam tablets; beta and non-beta-lactam capsules; oral liquids; dry syrups; and external preparations, such as nasal sprays, relief sprays, and creams.
Sotac Pharmaceuticals Limited Fundamentals Summary
| SOTAC fundamental statistics | |
|---|---|
| Market cap | ₹1.16b |
| Earnings (TTM) | ₹44.60m |
| Revenue (TTM) | ₹1.05b |
26.0x
P/E Ratio1.1x
P/S RatioIs SOTAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOTAC income statement (TTM) | |
|---|---|
| Revenue | ₹1.05b |
| Cost of Revenue | ₹823.10m |
| Gross Profit | ₹225.75m |
| Other Expenses | ₹181.15m |
| Earnings | ₹44.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.04 |
| Gross Margin | 21.52% |
| Net Profit Margin | 4.25% |
| Debt/Equity Ratio | 54.9% |
How did SOTAC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 09:15 |
| End of Day Share Price | 2025/02/12 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sotac Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.